Digital cardiac health company Eko Health has announced that clinicians in the UK can now purchase the company’s CORE 500 Digital Stethoscope, Eko+ membership, and a range of accessories through Eko’s website and Amazon UK. Eko provides healthcare professionals with tools to detect and monitor heart and lung conditions using digital stethoscopes, patient and provider software, and AI-powered analysis. The CORE 500 Digital Stethoscope supports both in-person and remote care with features such as AI insights, enhanced audio clarity, exam recording, waveform visualization, and a built-in 3-lead ECG. It also integrates with Eko’s mobile app for seamless data capture and sharing.
The Eko+ membership further enhances diagnostic capabilities with AI-enabled detection of heart murmurs, atrial fibrillation, bradycardia, and tachycardia, alongside guided multipoint auscultation and tools for recording and sharing clinical data. “Bringing Eko’s AI-powered technology directly to UK healthcare professionals represents an exciting step forward in expanding access to high-quality digital auscultation tools,” said David Bakey, general manager of consumer at Eko Health. “With CORE 500, Eko+, and a full range of accessories now available through EkoHealth.com, we're making it easier than ever for providers to integrate advanced stethoscope technology into their practice.”
Eko Health has been steadily expanding its suite of AI-enabled tools. In 2024, the company received FDA 510(k) clearance for its Low Ejection Fraction Tool (ELEFT), which helps detect low ejection fraction—a key indicator of heart failure—within 15 seconds during routine exams using an Eko stethoscope. ELEFT is part of Eko’s SENSORA Cardiac Early Detection Platform, which also includes FDA-cleared algorithms for identifying atrial fibrillation and structural heart murmurs.
In 2022, Eko was awarded a $2.7 million Small Business Innovation Research (SBIR) Direct Phase II grant from the National Institutes of Health to develop a machine learning algorithm for detecting and classifying pulmonary hypertension. This tool uses phonocardiogram (PCG) and ECG data gathered by Eko stethoscopes to identify high blood pressure in the lungs and the right side of the heart. That same year, the company also received FDA clearance for its Murmur Analysis Software, an algorithm that analyzes heart sounds, PCGs, and ECG signals to detect and categorize heart murmurs in both adult and pediatric patients, distinguishing between innocent and structural murmurs.
Click here to read the original news story.